Due to the strong correlations between retinal inflammation and RP progression, along with the activation of STAT3 in the Müller cells in both the Q344X and the X349E rhodopsin knock-in mouse models, we tested the hypothesis that pharmacological inhibition of the JAK/STAT pathways using an FDA-approved therapeutic can act to inhibit the JAK/STAT pathway in cultured Müller cells. The gene discussed is STAT3; the disease is retinitis pigmentosa 1.